Comparative Pharmacology
Head-to-head clinical analysis: BIMATOPROST versus DURYSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIMATOPROST versus DURYSTA.
BIMATOPROST vs DURYSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.
Prostaglandin analog; selective FP receptor agonist that increases uveoscleral outflow of aqueous humor.
One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.
One intracameral implant (10 mcg) administered in the study eye by a qualified ophthalmologist. A second administration may be performed if necessary, at least 3 months after the initial implant.
None Documented
None Documented
Clinical Note
moderateBimatoprost + Unoprostone
"Bimatoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateBimatoprost + Hydrochlorothiazide
"Bimatoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateBimatoprost + Epoprostenol
"Bimatoprost may increase the hypotensive activities of Epoprostenol."
Clinical Note
moderateVardenafil + Bimatoprost
"Vardenafil may increase the antihypertensive activities of Bimatoprost."
Terminal half-life: ~45 minutes (intravenous); after topical ocular administration, systemic half-life is similar due to rapid systemic clearance, with clinical effect lasting 24 hours due to ocular tissue binding
Not applicable due to local ocular administration with minimal systemic exposure; bimatoprost systemic half-life is approximately 45 minutes after intravenous administration.
Renal: <67% (unchanged and metabolites), Biliary/fecal: ~25%
Minimal systemic absorption; no data on specific routes of elimination; expected to be primarily excreted via renal and biliary routes in small amounts.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog